Clinical trials: Dry Eye
Dry Eye
Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye
To investigate that the efficacy of 3% DE-089 ophthalmic solution (one drop at a time, 6 times daily, 4 weeks topical administration), in comparison to 0.1% sodium hyaluronate ophthalmic solution (0.1% HA) (one drop at a time, 6…
- Trial name
- NCT01240382
- Testing
- 3% DE-089 ophthalmic solution, 0.1% sodium hyaluronate ophthalmic solution
- Where
- Japan
- Volunteers
- 332 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Meibomian Gland Dysfunction, Dry Eye Syndromes
to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction
A Randomized, Masked (Evaluator), Controlled, Prospective Study Evaluating the Effectiveness and Safety of the Tixel® Medical Device, Versus LipiFlow® in the Treatment of Meibomian Gland Dysfunction
- Conditions
- Meibomian Gland Dysfunction, Dry Eye Syndromes, Dry Eye
- Trial name
- NCT05162261
- Testing
- Tixel C, LipiFlow
- Where
- 5 sites in United States
- Volunteers
- 109 people
- Sponsor
- Novoxel Ltd.
Dry Eye
The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface
This study will test that hypothesis that topical administration of the FDA approved immunomodulatory agent cyclosporin A emulsion will minimize irritation and ocular surface disease that results from a short term low humidity…
- Trial name
- CsA (NCT02199964)
- Testing
- Cyclosporin 0.05% emulsion, Endura, Refresh artificial tears
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Baylor College of Medicine
Dry Eye Syndrome, Myopia
Clinical Evaluation of a Daily Disposable Contact Lens in Symptomatic Weekly/Monthly Lens Wearers
The purpose of this study was to evaluate the reduction of contact lens-related dryness symptoms when symptomatic weekly/monthly contact lens wearers were switched to DAILIES® AquaComfort Plus® lenses for a two-week period using…
- Trial name
- NCT01614600
- Testing
- Nelfilcon A contact lenses
- Volunteers
- 88 people
- Sponsor
- Alcon Research
Dry Eye Disease
Study Evaluating the Safety and Efficacy of AR-15512
This will be a Phase 3, multicenter, vehicle-controlled, double-masked, randomized study conducted at approximately 20 sites in the United States. All subjects enrolled will have dry eye disease (DED).
- Trial name
- COMET-2 (NCT05285644)
- Testing
- 0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution
- Where
- 23 sites in United States
- Volunteers
- 465 people
- Sponsor
- Aerie Pharmaceuticals
Keratoconjunctivitis Sicca
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
The purpose of this study is to determine whether 0.2% and 0.5% R348 Ophthalmic Solutions are safe and effective in the treatment of Patients with Keratoconjunctivitis Sicca.
- Trial name
- DROPS (NCT01900249)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 20 sites in United States
- Volunteers
- 204 people
- Sponsor
- Rigel Pharmaceuticals
Dry Eye Disease
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
The objective of this study is to assess the efficacy, safety, and tolerability of CyclASol Ophthalmic Solution in comparison to vehicle for the treatment of the signs and symptoms of DED.
- Trial name
- NCT03292809
- Testing
- CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
- Where
- 9 sites in United States
- Volunteers
- 328 people
- Sponsor
- Novaliq GmbH
Dry Eye Disease
Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease
Study Title: A Phase 4 Study to Assess the Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects with Dry Eye Disease
- Trial name
- NCT03287635
- Testing
- Corticotropin 80Unit/Ml Repository Injection
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Toyos Clinic
Dry Eye
A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes
The objective of this study was to compare the safety and efficacy of 0.10% and 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- VELOS-1 (NCT03334539)
- Testing
- HL036 ophthalmic solution
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- HanAll BioPharma Co., Ltd.
Dry Eye
Clinical Trial to Compare the Safety and Efficacy of Nanodrop®
Study design: Phase I-II clinical trial, comparative, non-inferiority with active control, parallel groups, double blind with randomisation.
- Trial name
- PRO-176/I (NCT04111965)
- Testing
- Nanodrop®, Systane Balance
- Where
- 6 sites in Mexico
- Volunteers
- 126 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Chalazion, Dry Eye Syndromes
Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye
The objective of this study is to evaluate the clinical utility, safety and effectiveness of the Manual Mini System compared to standardized warm compress therapy for application of controlled, localized heat therapy in adult…
- Trial name
- NCT00832130
- Testing
- Manual Mini System, iHeat Portable Warm Compress Therapy
- Where
- 11 sites in United States
- Volunteers
- 139 people
- Sponsor
- TearScience, Inc.
Dry Eye Syndrome
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects with Dry…
- Trial name
- NCT03404115
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.1%), Vehicle Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 300 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator
The primary objective of this study is to evaluate acute tear production as measured by tear meniscus height (TMH) captured by optical coherence tomography (OCT) after single use of the Oculeve Intranasal Neurostimulator (OIN) in…
- Trial name
- NCT02798289
- Testing
- Oculeve Intranasal Neurostimulator
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Oculeve, Inc.
Dry Eye Syndromes
Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy
This study will evaluate the safety and efficacy of cyclosporine 0.05% ophthalmic emulsion (Restasis®) in patients with dry eye disease.
- Trial name
- IMPACT (NCT02121847)
- Testing
- cyclosporine 0.05% ophthalmic emulsion, carboxymethylcellulose-based lubricant eye drops
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Allergan
Dry Eye Syndromes
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
This study evaluates the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally (active) compared with the same device applied extranasally (control) relating to symptoms of dry eye exacerbated by…
- Trial name
- NCT02910713
- Testing
- Intranasal Tear Neurostimulator
- Where
- 3 sites in United States
- Volunteers
- 185 people
- Sponsor
- Allergan
Dry Eye Disease (DED)
Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.
- Trial name
- NCT04036292
- Testing
- OC-01 (varenicline) nasal spray
- Where
- 22 sites in United States
- Volunteers
- 758 people
- Sponsor
- Oyster Point Pharma, Inc.
Xerophthalmia, Blepharitis
Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes
Systane Ultra is at least as efficacious and safe as Refresh Tears in Asian people with Dry Eyes
- Trial name
- NCT00796926
- Testing
- Systane Ultra eyedrops, Refresh eye drops
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Louis Tong
Sjogren's Syndrome
Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome
This study is a multi-national, multi-center, double-blind (sponsor open), randomized, placebo-controlled trial in subjects with active primary Sjögren's syndrome designed to understand the safety and tolerability profile of…
- Trial name
- NCT02631538
- Testing
- Belimumab, Rituximab
- Where
- 36 sites in Argentina, Canada and 8 more
- Volunteers
- 86 people
- Sponsor
- GlaxoSmithKline
Keratoconjunctivitis Sicca, Dry Eye Disease
Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
The purpose of the study is to evaluate the efficacy of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in the treatment of Dry Eye.
- Trial name
- OPUS-1 (NCT01421498)
- Testing
- Lifitegrast
- Where
- 13 sites in United States
- Volunteers
- 588 people
- Sponsor
- Shire
Dry Eye
Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)
SDP-4-CS201, is a Phase 2, multi-center, double-masked, randomized, vehicle-controlled, dose-response, parallel-group study designed to evaluate the ocular and systemic safety and efficacy of SDP-4 ophthalmic solution in subjects…
- Trial name
- SDP-4-CS201 (NCT03889886)
- Testing
- SDP-4 Ophthalmic Solution (0.1%), SDP-4 Ophthalmic Solution (1.0%), SDP-4 Ophthalmic Solution (3.0%)
- Where
- 26 sites in United States
- Volunteers
- 305 people
- Sponsor
- Silk Technologies, Ltd.